SCHEMBL5536974

SCHEMBL5536974

O=[N+]([O-])c1cn2c(n1)OC1(CCN(S(=O)(=O)c3ccccc3)CC1)C2

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.52
MAPK1 P28482 2/20 0.52
KMT2A Q03164 2/20 0.52
MEN1 O00255 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
POLB P06746 1/20 0.43
SMN1; SMN2 Q16637 5/20 0.42
HSD17B10 Q99714 2/20 0.41
HPGD P15428 1/20 0.41
CYP3A4 P08684 8/20 0.41
USP2 O75604 5/20 0.41
CYP1A2 P05177 5/20 0.41
CYP2D6 P10635 6/20 0.41
CYP2C9 P11712 5/20 0.40
TSHR P16473 2/20 0.40
CYP2C19 P33261 4/20 0.39
KCNH2 Q12809 1/20 0.39
HIF1A Q16665 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6424126 0.78 KCNH2 (0.44) ALDH1A1KMT2AKCNH2
SCHEMBL14562842 0.78 KCNH2 (0.40) ALDH1A1KMT2AMEN1KCNH2
SCHEMBL14965648 0.77 PKM (0.45) ALDH1A1MAPK1KMT2AMEN1L3MBTL1
SCHEMBL5543648 0.75 KCNH2 (0.40) ALDH1A1KMT2AMEN1HSD17B10KCNH2
SCHEMBL5546023 0.74 KCNH2 (0.41) ALDH1A1MAPK1KMT2AMEN1HSD17B10
SCHEMBL5543851 0.74 ALDH1A1 (0.45) ALDH1A1L3MBTL1POLBSMN1; SMN2HSD17B10
SCHEMBL5544251 0.74 KDM4E (0.41) ALDH1A1KMT2AMEN1
SCHEMBL6425174 0.74 MEN1 (0.44) ALDH1A1KMT2AMEN1L3MBTL1SMN1; SMN2
SCHEMBL14562825 0.74 KCNH2 (0.38) KCNH2
SCHEMBL5537616 0.73 NPY5R (0.48) ALDH1A1MAPK1KMT2AMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ALDH1A1 355/4885MAPK1 1392/4885KMT2A 4267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.